George J Weiner

This inventor holds 13 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Cancer Immunotherapy. Top assignees: University of Iowa Research Foundation, Checkmate Pharmaceuticals, Inc., Coley Pharmaceutical Gmbh. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George J Weiner. Retrieved from https://idiyas.com/inventor/george-j-weiner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 3)

% Patents Active = 76.9

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 470(Granted Patents)

Company Filing History:

10 out of 926

University of Iowa Research Foundation

patents

1 out of 6

Checkmate Pharmaceuticals, Inc.

patents

1 out of 27

Coley Pharmaceutical Gmbh

patents

4. 1 out of 1

Iowa Immunotherapy Investigators

Protein Design Labs, Inc.

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Tumor Immunotherapy

T-Cell Trafficking

Nucleic Acid Aptamers

Cytotoxic Particles

Immune Checkpoint Blockade

Biodegradable Formulations

Antibody-Induced Cell Lysis

Humanized Antibodies

Prostate Antigen-Specific Antibodies

Immunotherapeutic Oligonucleotides

Bispecific Antibodies

B-Cell Lymphoma

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12246031 - Compositions and methods for tumor immunotherapy (2025-03-11),

2. 12195744 - Identification of T-cell trafficking genes and uses thereof for increasing infiltration of T-cells into solid tumors (2025-01-14),

3. 10934549 - Nucleic acid aptamers (2021-03-02),

4. 10314854 - Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy (2019-06-11),

5. 9730988 - Parasitic biological agents for treatment and prevention of graft versus host disease (2017-08-15),

6. 9572894 - Biodegradable particulate formulations (2017-02-21),

7. 7723036 - Assessing response to anti-CD20 therapy by genotyping C1q components (2010-05-25),

8. 7534772 - Methods for enhancing antibody-induced cell lysis and treating cancer (2009-05-19),

9. 7381803 - Humanized antibodies against CD3 (2008-06-03),

10. 6512096 - Prostate cell surface antigen-specific antibodies (2003-01-28),

11. 6218371 - Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines (2001-04-17),

12. 6207805 - Prostate cell surface antigen-specific antibodies (2001-03-27),

13. 6129914 - Bispecific antibody effective to treat B-cell lymphoma and cell line (2000-10-10),

Title: Unveiling the Innovations of George J Weiner

Introduction:

George J Weiner, a prolific inventor based in Iowa City, IA (US), has made significant contributions to the field of biotechnology with a total of 11 patents to his name. His groundbreaking work has the potential to revolutionize cancer treatment and diagnosis, showcasing his prowess in the realm of scientific innovation.

Latest Patents:

Among his latest patents is the development of Nucleic acid aptamers, where compositions comprising an aptamer bound to a complex show promise in impacting polypeptides. Additionally, his work on methods for treating tumors in situ is a beacon of hope in the fight against cancer, utilizing a combination of cytotoxic particles, immune checkpoint inhibitors, and T-cell stimulatory agents.

Career Highlights:

Weiner has honed his craft at reputable institutions such as the University of Iowa Research Foundation and Protein Design Labs, Inc., where his innovative spirit found fertile ground for exploration. His relentless pursuit of scientific excellence has led to a remarkable patent portfolio that continues to inspire awe in the biotech industry.

Collaborations:

Throughout his career, Weiner has collaborated with esteemed individuals in the field, including Roger Gingrich and Brian K Link. These partnerships have not only enriched his research endeavors but have also paved the way for transformative advancements in biotechnology.

Conclusion:

In conclusion, George J Weiner stands as a trailblazer in the realm of biotechnological innovations, with a keen eye for pioneering solutions that have the potential to shape the future of cancer treatment. His remarkable journey serves as a testament to the power of innovation and the enduring impact of visionary inventors in propelling scientific progress forward.

Profile summary based on public USPTO records.